VX-950 and Peginterferon for Hepatitis C
Phase 1
Completed
- Conditions
- Hepatitis C
- Registration Number
- NCT00251199
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Brief Summary
VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- infected with Hepatitis C virus
Exclusion Criteria
- contraindications to peginterferon therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Viral kinetics
- Secondary Outcome Measures
Name Time Method Assess the safety of VX-950 in combination with peginterferon
Trial Locations
- Locations (1)
Call for information
🇳🇱Amsterdam, Netherlands
Call for information🇳🇱Amsterdam, Netherlands